---
title: "Aldesleukin - Acute Myeloid Leukemia, Disease"
sidebar: mydoc_sidebar
permalink: db00041-mesh-d015470-1.html
toc: false 
---


Path ID: `DB00041_MESH_D015470_1`
{% include image.html url="images/db00041-mesh-d015470-1.png" file="db00041-mesh-d015470-1.png" alt="db00041-mesh-d015470-1" %}

## Concepts

|------------|------|---------|
| Identifier | Name | Type    |
|------------|------|---------|
| MESH:C082598 | Aldesleukin | Drug |
| UniProt:P14784 | Interleukin-2 receptor subunit beta | Protein |
| UniProt:P01589 | Interleukin-2 receptor subunit alpha | Protein |
| GO:0038110 | Interleukin-2-mediated signaling pathway | BiologicalProcess |
| GO:0045065 | Cytotoxic T cell differentiation | BiologicalProcess |
| GO:0030101 | Natural killer cell activation | BiologicalProcess |
| MESH:D015470 | Acute myeloid leukemia, disease | Disease |
|------------|------|---------|

## Relationships

|---------|-----------|---------|
| Subject | Predicate | Object  |
|---------|-----------|---------|
| Aldesleukin | INCREASES ACTIVITY OF | Interleukin-2 Receptor Subunit Beta |
| Interleukin-2 Receptor Subunit Beta | POSITIVELY REGULATES | Interleukin-2-Mediated Signaling Pathway |
| Aldesleukin | INCREASES ACTIVITY OF | Interleukin-2 Receptor Subunit Alpha |
| Interleukin-2 Receptor Subunit Alpha | POSITIVELY REGULATES | Interleukin-2-Mediated Signaling Pathway |
| Interleukin-2-Mediated Signaling Pathway | POSITIVELY REGULATES | Cytotoxic T Cell Differentiation |
| Interleukin-2-Mediated Signaling Pathway | POSITIVELY REGULATES | Natural Killer Cell Activation |
| Cytotoxic T Cell Differentiation | TREATS | Acute Myeloid Leukemia, Disease |
| Natural Killer Cell Activation | TREATS | Acute Myeloid Leukemia, Disease |
|---------|-----------|---------|

Reference: 
  - [https://go.drugbank.com/drugs/DB00041](https://go.drugbank.com/drugs/DB00041)
